HCA Health Inc vs Vaxcyte Inc. Common Stock — how do they compare? HCA Health Inc trades at $470.49 (market cap $99.75B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: HCA Health Inc is far larger — about 9.5× Vaxcyte Inc. Common Stock's market cap, and HCA Health Inc pays a 0.68% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| HCA | PCVX | |
|---|---|---|
Market Cap | $99.75B | $10.51B |
Volume | 1,083,231 | 2,644,694 |
Sector | Health | Health |
52-Week High | $545.13 | $73.82 |
52-Week Low | $361.32 | $40.32 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $150.29B | $9.14B |
Dividend Yield | 0.68% | — |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.
The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →